METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence

被引：0
|
作者：
Le, X. [1 ]
Aggarwal, C. [2 ]
Simmons, A. [3 ]
Crawford, S. A. [3 ]
Ng, S. [3 ]
Chen, C. [3 ]
Karve, S. [3 ]
Stein, S. [3 ]
Woll, K. [3 ]
Ansell, P. J. [3 ]
Mistry, A. [3 ]
Bryant, D. [4 ]
Wistuba, I. I. [1 ]
机构：
[1] MD Anderson, Thorac Head & Neck, Houston, TX USA
[2] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Penn Ctr Canc Care Innovat, Philadelphia, PA USA
[3] AbbVie Inc, US Med Affairs, N Chicago, IL USA
[4] Caris Life Sci, Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1360
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1303P
引用
收藏
页码：S829 / S829
页数：1
相关论文
共 50 条
  • [41] PROTEIN OVEREXPRESSION OF C-MET HAS A SIGNIFICANT IMPACT ON SURVIVAL IN PATIENTS WITH UTERINE CERVICAL ADENOCARCINOMA
    Seo, S.
    Kim, W. Y.
    Shim, S-H
    So, K. A.
    Kim, T. J.
    Lee, S. J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A267 - A267
  • [42] The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas
    Nakajima, M
    Sawada, H
    Yamada, Y
    Watanabe, A
    Tatsumi, M
    Yamashita, J
    Matsuda, M
    Sakaguchi, T
    Hirao, T
    Nakano, H
    CANCER, 1999, 85 (09) : 1894 - 1902
  • [43] Protein overexpression of c-MET has a significant impact on survival in patients with uterine cervical adenocarcinoma
    Lee, J. Y.
    Kim, W. Y.
    Shim, S. H.
    Park, J. H.
    So, K. A.
    Kim, T. J.
    Lee, S. J.
    Park, H. K.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 180 - 181
  • [44] The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas
    Carneiro, F
    Sobrinho-Simoes, M
    CANCER, 2000, 88 (01) : 238 - 239
  • [45] Prognostic Value and Clinical Pathology of MACC-1 and c-MET Expression in Gastric Carcinoma
    Ma, Jie
    Ma, Jun
    Meng, Qun
    Zhao, Zhong-Sheng
    Xu, Wen-juan
    PATHOLOGY & ONCOLOGY RESEARCH, 2013, 19 (04) : 821 - 832
  • [46] Prognostic and predictive Value of Osteopontin, c-Met, and HGF in Patients with locally advanced Rectal Cancer
    Dalkmann, T.
    Wohlleben, G.
    Schlegel, N.
    Gasser, M.
    Waaga-Gasser, A. -M
    Flentje, M.
    Polat, B.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S190 - S190
  • [47] Prognostic Value of c-MET and CA9 Tumoral Expression in Hepatocellular Carcinoma (HCC)
    Paradis, V.
    Tijas-Raballand, A.
    Albuquerque, M.
    Neuzillet, C.
    Bladt, F.
    Ihling, C.
    Klevesath, M.
    Zheng, H.
    Raymond, E.
    De Gramont, A.
    Bedossa, P.
    Faivre, S.
    LABORATORY INVESTIGATION, 2014, 94 : 426A - 426A
  • [48] Soluble C-Met as a Biomarker of Clinical Outcomes After STEMI
    不详
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 2348 - 2348
  • [49] Prognostic Value of c-MET and CA9 Tumoral Expression in Hepatocellular Carcinoma (HCC)
    Paradis, V.
    Tijas-Raballand, A.
    Albuquerque, M.
    Neuzillet, C.
    Bladt, F.
    Ihling, C.
    Klevesath, M.
    Zheng, H.
    Raymond, E.
    De Gramont, A.
    Bedossa, P.
    Faivre, S.
    MODERN PATHOLOGY, 2014, 27 : 426A - 426A
  • [50] Urinary c-Met, a novel biomarker of metastatic prostate cancer
    Wernick, M.
    Russo, A. L.
    Jedlicka, K.
    McNally, D.
    Shankavaram, U.
    Kaushal, A.
    Dahut, W.
    Citrin, D.
    Bottaro, D. P.
    Camphausen, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S57 - S58
12345